Undergoing acupuncture significantly reduced joint pain related to treatment with aromatase inhibitors in postmenopausal women with early-stage breast cancer.
Treatment with gonadotropin-releasing hormone analog can safely and effectively protect ovarian function and has the potential to preserve fertility in premenopausal women undergoing chemotherapy for early-stage breast cancer.
Although a longer progression-free survival is of high importance to CLL patients, a reduced risk of serious adverse events might be worth a tradeoff for some efficacy.
The FDA approved a biosimilar for trastuzumab, Ogivri, for the treatment of patients with HER2-positive breast and stomach cancer.
Treatment with crizotinib resulted in objective responses in patients with advanced papillary renal cell carcinoma type 1 with MET mutations or amplification.
Use of two BEACOPP regimens that incorporated brentuximab resulted in improved rates of complete response and complete remission at the end of treatment.
More than half of young adult cancer patients reported ongoing problems related to sexual function during the first 2 years after their cancer diagnosis.
Elevated pre-transplant C-reactive protein was associated with worse overall survival in patients who underwent autologous stem cell transplantation for multiple myeloma, particularly in those who had transplant more than 12 months after diagnosis.
Treatment with the anti–PD-1 antibody pembrolizumab resulted in durable antitumor activity with manageable side effects in patients with heavily pretreated, PD-L1–positive advanced esophageal carcinoma, according to phase IB results of the KEYNOTE-028 study.
The combination of olaparib plus paclitaxel failed to significantly improve overall survival compared with placebo plus paclitaxel in Asian patients with advanced gastric cancer, according to the phase III results of the GOLD study.